All In Biotech

NDA 209501 · Upjohn

Lyrica Cr

Pregabalin · Oral

Last checked: Nov 20, 2026Latest source record: Apr 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Oct 11, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

564

150 Phase 3, 40 recruiting

FAERS reports

81,701

70,818 serious, 12,465 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 12, 2026.

LYRICA CR is indicated for the management of: • Neuropathic pain associated with diabetic peripheral neuropathy • Postherpetic neuralgia Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures. LYRICA CR is indicated for the management of: • Neuropathic pain associated with diabetic peripheral neuropathy (DPN) ( 1 ) • Postherpetic neuralgia (PHN) ( 1 ) Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.

Mechanism: Pregabalin binds with high affinity to the alpha 2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin) suggest that binding to the alpha 2 ‑delta subunit may be involved in pregabalin’s anti‑nociceptive and antiseizure effects in animals. In animal models of nerve damage, pregabalin has been shown to reduce calcium‑dependent release of pro‑nociceptive...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 11, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
3 products under this application
  • LYRICA CR · PREGABALIN 330MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • LYRICA CR · PREGABALIN 82.5MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • LYRICA CR · PREGABALIN 165MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Pregabalin" as an intervention, any sponsor and status, largest first.

All 564 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective7,667
  • off label use5,813
  • fatigue5,735
  • pain5,131
  • nausea5,086
  • toxicity to various agents4,777
  • headache4,473
  • dyspnoea4,269
  • dizziness4,260
  • diarrhoea3,888
  • vomiting3,775
  • malaise3,495

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20054
200659
2007211
2008462
2009367
2010548
2011572
2012826
20131,053
20141,156
20151,630
20162,144
20172,596
20184,082
20195,849
20207,546
20218,337
20228,622
20238,290
20249,820
20259,917
20267,607

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lyrica Cr (Pregabalin)

2024 spending

$311K

Beneficiaries

76

300 claims

Per beneficiary

$4,097

$15.61 per unit

View as table
YearSpending
2020$2,721,855
2021$1,930,086
2022$450,459
2023$402,333
2024$311,397

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,057 on PubMed

Sponsor: Upjohn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.